Back to results
US 10,308,703 B2Granted
Variants of DR3 and use thereof
AssigneeThe National Institute for Biotechnology I
InventorsAmir Aharoni, Itay Levin
Life of this patent
Estimating the term…
Abstract
Death-domain receptor 3 (DR3) variants having increased binding affinity to TL1A, and composition comprising same, are provided. Further, methods of use of said peptides or composition, including, but not limited to treatment of autoimmune and/or inflammatory disease are provided.
Claims10
An amino acid molecule, comprising the amino acid sequence of GGTRSPRCDCAGDFHKKIGLFCCRGCPAGHYLKAPCTEPCGNSTCLVCPQDTFLAWE NHHNSECARCQACDEQASQVALENCSAVADTRCGCKPGWFVECQVSQCVSSSPFYCQ PCLDCGALHRHTRLLCSRRDTDCGTCLPGFYEHGDGCVSCPTSTLGSCPERCAAVCGW RQMF set forth in SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.